Desmoid Tumors Market Poised for 6.8 % Growth, Set to Hit $4.13 Billion by 2029

How Are the key drivers contributing to the expansion of the desmoid tumors market?
The escalating prevalence of cancer is predicted to catalyze the expansion of the desmoid tumor market. Cancer is characterized by abnormal cellular growth in the body, which can uncontrollably spread and potentially damage nearby tissues and organs. With global cancer rates climbing, there has been a corresponding surge in demand for refined chemotherapeutic agents, having a favorable impact on the desmoid tumor market. The National Cancer Institute, a US Federal Government agency, reported in May 2024 that estimated new cancer diagnoses in the U.S in 2024 would be 2,001,140, leading to 611,720 deaths. Additionally, in 2022, worldwide, nearly 20 million new cases were reported with 9.7 million related fatalities. The institution predicts that by 2040, global new cancer cases will reach 29.9 million per year, and deaths could rise to 15.3 million. Hence, increasing cancer rates are propelling the desmoid tumor market's development. Funding from the government dedicated to research and development is predicted to fuel the ascent of the desmoid tumor market. This funding, which essentially constitutes financial support from the government for specific purposes, is instrumental in promoting tumor studies and treatment. It provides resources for scientific investigations, medical facilities, and patient accessibility, thereby bettering cancer prevention, detection, and patient results. For example, in September 2023, the National Cancer Institute, a US governmental agency, was allocated a budget of $7.3 billion for the Cancer Moonshot in the fiscal year 2023 by the United States Congress, denoting a $408 million surge from 2022. Therefore, an uptick in government funding for research and development is steering the progress of the desmoid tumor market.

Get Your Desmoid Tumors Market Report Here:
https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

What growth opportunities are expected to drive the desmoid tumors market's CAGR through 2034?
Significant growth has been observed in the market size of desmoid tumors in recent years. It's projected to expand from $2.97 billion in 2024 to $3.18 billion in 2025, yielding a compound annual growth rate (CAGR) of 7.3%. The remarkable growth observed during the historic period can be attributed to advancements such as medical imaging, genetic research insights, surgical innovations, heightened awareness, education measures, and patient advocacy.

The market for desmoid tumors is anticipated to witness robust expansion in the upcoming years, with an estimated value of $4.13 billion by 2029, at a compound annual growth rate (CAGR) of 6.8%. The main factors contributing to this predicted growth during the forecast period include targeted treatments, personalized healthcare, augmented global collaborations, regulatory consent for innovative therapies, and a more patient-focused methodology. The forecast period also expects trends such as progressive treatment techniques, precision medical treatment, discovery of biomarkers, research initiatives and clinical trials, teams specializing in multiple treatments, and elevated patient advocacy and support.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp

What are the emerging trends shaping the future of the desmoid tumors market?
Prominent entities in the desmoid tumors market are focusing on the creation of innovative medications such as nirogacestat to better address the requirements of their current consumers. Nirogacestat functions as an oral, small-molecule gamma-secretase inhibitor. For example, in February 2023, U.S-based clinical-stage biopharmaceutical firm, SpringWorks Therapeutics Inc., disseminated news of the acceptance and priority review by the U.S. Food and Drug Administration (FDA) for their fresh drug application (NDA) for nirogacestat designed to treat adults battling desmoid tumors. Nirogacestat supposedly operates by inhibiting the creation of notch proteins, potentially causing the demise of tumor cells. Desmoid tumors are known to produce a high concentration of notch proteins, believed to stimulate their growth. Furthermore, nirogacestat offers patients a fresh possible treatment avenue, potentially elevating results.

Which growth-oriented segments of the desmoid tumors market are leading the industry's development?
The desmoid tumors market covered in this report is segmented -

1) By Treatment: Surgery, Radiation Therapy, Anti-Inflammatory Medication, Hormone Therapy, Chemotherapy, Novel Molecular-Targeted Therapy, Other Treatments
2) By Diagnosis: Biopsy, Electron Microscopic Examination, Immunohistochemical Analysis, Other Diagnosis
3) By End-User: Hospitals And Clinics, Specialty Centers, Other End-Users

Subsegments:
1) By Surgery: Wide Excision, Minimally Invasive Surgery
2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy
3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids
4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors
5) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy
6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Therapies
7) By Other Treatments: Watchful Waiting, Physical Therapy, Pain Management Strategies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13228

What regions are leading the charge in the desmoid tumors market?
North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What companies are at the forefront of innovation in the desmoid tumors market?
Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp

What Is Covered In The Desmoid Tumors Global Market Report?

• Market Size Forecast: Examine the desmoid tumors market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the desmoid tumors market for a structured understanding.
• Key Players Overview: Analyze major players in the desmoid tumors market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the desmoid tumors market.
• Segment Contributions: Evaluate how different segments drive overall growth in the desmoid tumors market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the desmoid tumors market.
• Industry Challenges: Identify potential risks and obstacles affecting the desmoid tumors market.
• Competitive Landscape: Review strategic developments in the desmoid tumors market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.